PHARMACEUTICAL 2021

Monopar Therapeutics
Rank 66 of 394



PHARMACEUTICAL 2021

Monopar Therapeutics
Rank 66 of 394

Monopar Therapeutics

The relative strengths and weaknesses of Monopar Therapeutics are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Monopar Therapeutics compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 143% points.The greatest weakness of Monopar Therapeutics is the variable Other Revenues, reducing the Economic Capital Ratio by 12% points.

The company's Economic Capital Ratio, given in the ranking table, is 375%, being 119% points above the market average of 256%.

Input Variable	Value in 1000 USD
Assets, Current	16,800
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,177
Liabilities, Non-Current	0
Other Assets	69
Other Compr. Net Income	3.1
Other Expenses	0
Other Liabilities	0
Other Net Income	82
Other Revenues	122
Property and Equipment	0
Research and Development	4,065
Selling, General and Administrative Expense	2,444

Output Variable	Value in 1000 USD
Assets	16,869
Liabilities	1,177
Expenses	6,509
Revenues	122
Stockholders Equity	15,692
Net Income	-6,305
Comprehensive Net Income	-6,303
BaseVar	12,381
ECR before LimitedLiability	309%
Economic Capital Ratio	375%